Neoplasms

All Conditions

Blood and Lymph Conditions

Immune System Diseases

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Nervous System Diseases

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Rare Diseases

Sarcoma

Lymphoma

Virus Diseases

Osteosarcoma

Wilms Tumor

Neuroblastoma

Sarcoma, Ewing

Vaccinia

Rhabdomyosarcoma

Nerve Sheath Neoplasms

Neurofibrosarcoma

Neoplasms by Histologic Type

Neoplasms, Connective and Soft Tissue

Neuroectodermal Tumors, Primitive, Peripheral

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Neuroepithelial

Neoplasms, Germ Cell and Embryonal

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Myosarcoma

Neoplasms, Bone Tissue

Neoplasms, Connective Tissue

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Syndrome

Neoplastic Syndromes, Hereditary

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Genetic Diseases, Inborn

Communicable Diseases

Poxviridae Infections

DNA Virus Infections

Soft Tissue Sarcoma

Lymphosarcoma

Wilms' Tumor

Ewing Sarcoma

Malignant Peripheral Nerve Sheath Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Molgramostim

Sargramostim

Immunologic Factors

Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.

Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Timothy Cripe, MD, PhD

This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard therapies. Tumors are likely to include neuroblastoma, lymphoma, Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcomas, and malignant peripheral nerve sheath tumors. Benign tumors are excluded. These tumor types were selected because evidence of biological activity was observed in cancer cells lines and ex vivo infected primary human tissue samples, specifically pediatric cancer types such as sarcomas and neuroblastomas.

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors.

Determine the maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by intratumoral (IT) injection in pediatric patients with advanced/metastatic, unresectable refractory solid tumors

Solving Kids' Cancer

Jennerex Biotherapeutics

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients	NCT01169584	Neuroblastoma Rhabdomyosarcom... Lymphoma Wilm's Tumor Ewing's Sarcoma	Recombinant Vac...	2 Years - 21 Years	SillaJen, Inc.
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients	NCT01169584	Neuroblastoma Rhabdomyosarcom... Lymphoma Wilm's Tumor Ewing's Sarcoma	Recombinant Vac...	2 Years - 21 Years	SillaJen, Inc.

Spots Global Cancer Trial Database for advanced metastatic pediatric solid tumors